Revvity Inc. logo

Revvity Inc. (RVTY)

Market Open
16 Oct, 04:13 PM
NYSE NYSE
$
153. 22
-1.49
-0.9631%
$
16.97B Market Cap
- P/E Ratio
0.28% Div Yield
495,647 Volume
- Eps
$ 154.71
Previous Close
Add Transaction
Day Range
152.48 155.5
Year Range
81.22 166.25
Want to track RVTY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Revvity to Report Q2 Earnings: What's in Store for the Stock?

Revvity to Report Q2 Earnings: What's in Store for the Stock?

Revvity, Inc.  RVTY is slated to report second-quarter 2026 results on Aug. 4, before market open.

Zacks | 2 months ago
Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 2 months ago
Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs

Revvity Develops High-Throughput T-SPOT.TB Platform for Clinical Labs

RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.

Zacks | 2 months ago
Revvity to Launch Signals for Startups for Emerging Biotech Companies

Revvity to Launch Signals for Startups for Emerging Biotech Companies

RVTY's Signals for Startups gives early-stage biotechs scalable software and guided onboarding to streamline research and support future growth.

Zacks | 2 months ago
Revvity Expands Signals AI With Anthropic Claude Integration

Revvity Expands Signals AI With Anthropic Claude Integration

RVTY expands Signals AI through Anthropic's MCP ecosystem, giving scientists secure Claude access to connected R&D data and scientific context.

Zacks | 3 months ago
Revvity Launches Signals AI to Advance Scientific R&D Workflows

Revvity Launches Signals AI to Advance Scientific R&D Workflows

RVTY expands AI capabilities in Signals software with Signals AI, designed to help scientists turn connected R&D data into actionable insights.

Zacks | 3 months ago
Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seekingalpha | 4 months ago
Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

Zacks | 4 months ago
RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

Zacks | 5 months ago
RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

RVTY Q1 Earnings Beat Estimates on Organic Growth & Strong Execution

Revvity beat Q1 EPS and revenue estimates as 3% organic growth and portfolio execution offset margin pressure and China ImmunoDx divest plans.

Zacks | 5 months ago
Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Seekingalpha | 5 months ago
Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics

Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks | 5 months ago
Loading...
Load More